Intersect ENT Inc. closes a $30 million round of financing to commercialize its first product, a stent-based treatment for sinusitus.

Intersect ENT Inc. completed a $30 million funding round, the company said.
The millions of dollars in fees that medical device companies pay for FDA review aren't exempt from...
EnteroMedics expects to file for pre-market approval from the FDA this quarter for its Maestro vagal...
Natus Medical beats Wall Street's earnings forecast with a 1,000-fold profit surge on record sales,...
The U.S. Supreme Court agrees to hear Medtronic's appeal of a patent infringement loss to rival...
The New York Times lists the 10 most expensive hospitals in the United States, based on CMS data